Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...

Steven Cress reviews the investing year that was and his top 10 stocks for 2025, which returned 45.6% vs S&P 500's 17.6%.

I remain bullish on US equities into 2026, expecting a 10% S&P 500 return, with small caps likely to outperform. Learn more about market outlook here.

Curt Isakson reminds that fires at commercial buildings are bigger, hotter, faster and more complex than fires at residences ...

Explore the essential role of India’s market infrastructure institutions (MIIs). As demat accounts cross the 16-crore ...

Background Non-communicable diseases (NCDs) are the leading cause of death and morbidity worldwide, responsible for 7 out of ...

Full-Year Guidance Maintained -- Management reaffirmed guidance for organic revenue growth of 1%-4%, adjusted EBITDA growth ...

Objectives Hypertension and depression frequently co-occur, complicating patient management and worsening outcomes. This scoping review aims to systematically map non-pharmacological interventions for ...

Aim The Royal Dutch Society for Physical Therapy (KNGF) instructed a multidisciplinary group of Dutch anterior cruciate ligament (ACL) experts to develop an evidence statement for rehabilitation after ...

Since we started this annual exercise in 2015, we have outperformed the market in nine of the 11 years. On average, the portfolio delivered an impressive return of 22.9% per year.

Roku ROKU is entering a stronger phase of its turnaround as improving margins and disciplined execution reshape expectations ...

Monthly dividend stocks go above and beyond the norm, in more ways than one. If you ever think you have it rough as an income ...